Source: Pharmacy Times articles
The approval expands the prior indication of idecabtagene vicleucel (Abecma; Bristol Myers Squibb), which will make the drug available to patients in earlier lines.
Read More
by | Apr 5, 2024 | Myeloma News | 0 comments
Source: Pharmacy Times articles
The approval expands the prior indication of idecabtagene vicleucel (Abecma; Bristol Myers Squibb), which will make the drug available to patients in earlier lines.
Read More